AI assistant
Sending…
Vanda Pharmaceuticals Inc. — Director's Dealing 2025
Feb 25, 2025
33390_dirs_2025-02-24_c87e4666-4d67-4aa0-a5e5-524b97ee671a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2025-02-21
Reporting Person: Moran Kevin Patrick (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-21 | Common Stock | P | 2000 | $4.3894 | Acquired | 355763 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 635 | Indirect |
More from Vanda Pharmaceuticals Inc.
Regulatory Filings
2026
Jun 5
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 5
Interim / Quarterly Report
2026
May 7
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Board/Management Information
2026
Apr 22
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Feb 24
Regulatory Filings
2026
Feb 23
Director's Dealing
2026
Feb 19